Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apellis Pharmaceuticals Inc.

19.58
+0.19000.98%
Post-market: 19.580.00000.00%17:09 EDT
Volume:1.72M
Turnover:33.76M
Market Cap:2.46B
PE:-10.90
High:19.96
Open:19.48
Low:19.30
Close:19.39
Loading ...

Apellis Pharmaceuticals Inc - Pdufa Target Action Date for Empaveli Is July 28, 2025

THOMSON REUTERS
·
01 Apr

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for Empaveli® (Pegcetacoplan) for C3g and Primary Ic-Mpgn

THOMSON REUTERS
·
01 Apr

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

GlobeNewswire
·
01 Apr

Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts

Insider Monkey
·
26 Mar

Evercore ISI Remains a Buy on Apellis Pharmaceuticals (APLS)

TIPRANKS
·
24 Mar

U.S. RESEARCH ROUNDUP-American Electric Power, Block, Lenz Therapeutics

Reuters
·
18 Mar

Apellis Pharmaceuticals Inc : JP Morgan Cuts Target Price to $45 From $54

THOMSON REUTERS
·
18 Mar

Apellis Pharmaceuticals (APLS) Gets a Hold from Mizuho Securities

TIPRANKS
·
07 Mar

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Benzinga
·
06 Mar

UBS Adjusts Apellis Pharmaceuticals Price Target to $43 From $45, Maintains Buy Rating

MT Newswires Live
·
05 Mar

Stock Track | Apellis Pharmaceuticals Soars 5.07% as JP Morgan Maintains Overweight Rating

Stock Track
·
05 Mar

Apellis Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
05 Mar

Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues

Zacks
·
03 Mar

Apellis Pharmaceuticals Is Maintained at Neutral by Wedbush

Dow Jones
·
03 Mar

Apellis Pharmaceuticals Inc : Wedbush Cuts Target Price to $29 From $30

THOMSON REUTERS
·
03 Mar

Apellis Pharmaceuticals (APLS) Receives a Hold from Scotiabank

TIPRANKS
·
03 Mar

Apellis Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Mar

RBC Trims Price Target on Apellis Pharmaceuticals to $25 From $26, Keeps Sector Perform Rating

MT Newswires Live
·
03 Mar

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS), DENTSPLY SIRONA (XRAY) and Cytokinetics (CYTK)

TIPRANKS
·
03 Mar

Apellis price target lowered to $44 from $47 at BofA

TIPRANKS
·
03 Mar